O nyx (Micro Therapeutics, Inc.) is a nonadhesive liquid embolic agent composed of ethylene vinyl alcohol copolymer suspended in DMSO with tantalum added for radiopacity. The FDA initially approved it in 2005 for the treatment of cerebral arteriovenous malformations. Onyx has since gained widespread use, and its applications have expanded to the embolization of spinal and cranial arteriovenous fistulas, tumors, and, more recently, aneurysms. The role of Onyx in the treatment of CCFs, however, has not been well-documented and has been largely limited to case reports and small case series. Furthermore, complications associated with Onyx-based embolization have not been emphasized in the literature. We therefore present our early experience in an attempt to determine the safety and efficacy of Onyx-based embolization of CCFs.
nostic catheter was maneuvered into the ipsilateral cervical CA. A 4 Fr Terumo catheter was maneuvered through the venous system into the IPS or, less commonly, the origin of the facial vein followed by navigation of an Echelon microcatheter (ev3 Inc.) into the cavernous sinus under roadmap guidance. Angiography was performed through the microcatheter to confirm catheter position within the cavernous sinus and better delineate the cavernous sinus drainage. The dead space within the microcatheter was slowly filled with DMSO, and this was followed by Onyx embolization using a subtracted roadmap. The concentration of Onyx was chosen based on the rapidity of flow within the fistula as determined by the microcatheter angiogram. In cases of fistulas with feeders from the ICA, a Hyperform balloon (ev3 Inc.) was simultaneously navigated across the cavernous CA and inflated during embolization to prevent inadvertent migration of Onyx into the CA. In such cases heparin was administered to maintain activated clotting times between 250-300 seconds. The balloon was intermittently deflated after ~ 2 minutes, and an arterial angiogram was obtained to assess the degree of cavernous sinus embolization and fistula closure. In cases of high-flow fistulas, coils were placed at the takeoff of the SOV and occasionally within the cavernous sinus to slow the flow through the fistula and act as a mesh, thereby decreasing the incidence of migration of embolic material distally into the vein.
Transarterial Embolization
Percutaneous femoral artery access was achieved using a 65-cm 6 Fr sheath. Heparinization was used to maintain activated clotting times between 250-300 seconds. A 6 Fr Envoy guide catheter (Cordis) was maneuvered into the CA and this was followed by selective catheterization of feeding vessels using an Echelon microcatheter (ev3 Inc.). Angiography was performed via the microcatheter to better delineate the fistula and to recognize potentially dangerous anastomoses. The dead space within the microcatheter was slowly filled with DMSO followed by Onyx embolization using a subtracted roadmap. In Barrow Type A CCFs, a Rebar microcatheter (ev3 Inc.) was navigated through the fistulous point into the cavernous sinus, and embolization with high-density Onyx 500 was conducted while simultaneously inflating a Hyperglide balloon (ev3 Inc.) in the cavernous ICA to prevent reflux into the parent artery. In such a case, a 7 Fr femoral sheath and Envoy guide catheter were used.
Results

Outcomes of Embolization
A total of 12 patients (5 males and 7 females, age 24-88 years) with CCFs underwent Onyx-based embolization . Patient demographics, clinical presentation, and type of fistula are detailed in Table 1 . There were 1 Barrow Type A, 1 Type B, 3 Type C, and 7 Type D fistulas. Embolization was performed via a transvenous route in 8 cases and via a transarterial route in 4 cases. Transvenous access to the cavernous sinus was achieved through the IPS in all but 3 cases, in which catheters were inserted via the SOV, one of which required direct venous cut-down. Onyx 34 was used in all but 2 cases: a direct Type A fistula embolized with Onyx 500 and an indirect Type C fistula embolized with Onyx 18. Adjuvant embolization with framing coils was performed in 7 cases ( Table 2 ). All procedures were completed in a single session. The patency of the ICA was achieved in all but 1 patient (Case 8). This was a patient with multiple dural fistulas including a complex Type D CCF; this patient had undergone a previous unsuccessful attempt at NBCA-based transarterial obliteration of the lesion as well as a failed attempt at transvenous embolization. After passing a balloon test occlusion, the fistula was ultimately treated by transarterial Onyx embolization of the cavernous sinus and by subsequent occlusion of the ICA with coils. Immediate fistula obliteration was complete in all cases. Clinical resolution of presenting symptoms occurred in 100% of the patients by 2 months. Radiographic follow-up data (mean 16 months, range 4-35 months) were available in 6 patients with complete resolution in all. 
Complications
Neurological complications occurred in 3 patients. One patient developed a complete CN VII palsy that has not resolved. Two patients developed transient neuropathies: one patient had a Horner syndrome and partial CN VI palsy, which resolved by 4 months, and the other had a complete CN III and partial CN V palsy, which resolved by 3 months.
Illustrative Cases
Case 10: Transvenous Embolization Without a Balloon
This 81-year-old woman presenting with a 3-week history of diplopia was found to have right eye chemosis, proptosis, and a complete CN VI palsy on examination. Intraocular pressure was 21 mm Hg in the right eye. Diagnostic cerebral angiography demonstrated a Barrow Type C CCF fed by meningeal branches of the right ECA ( Fig.  1a and b) . The contralateral IPS was catheterized after multiple unsuccessful attempts at accessing the ipsilateral IPS. An Echelon microcatheter was then navigated across intercavernous channels to the ipsilateral cavernous sinus ( Fig. 1c and d) . A microangiogram demonstrated the position of the microcatheter in the anterior compartment of the cavernous sinus and rapid retrograde flow through the SOV. A coil was deployed at the proximal end of the SOV to prevent migration of the embolic material distally into the vein (Fig. 1e) . We then performed embolization with 2 ml of Onyx 34 while using subtracted roadmap guidance. Final angiography demonstrated complete obliteration of the CCF (Fig. 1f-h ).
Case 4: Transvenous Embolization With a Balloon
This 24-year-old woman presenting with a 2-week history of headaches and left periorbital pain was found to have a Barrow Type D CCF fed by the left meningohypophysial trunk and the left ECA, with drainage into the SOV (Fig. 2a and b) . Access to the cavernous sinus was gained via the ipsilateral IPS, and a coil was inserted at the takeoff of the SOV (Fig. 2c) . Embolization was performed using Onyx 34 while simultaneously inflating a Hyperform balloon in the cavernous CA (Fig. 2d) . Final angiography demonstrated complete obliteration of the fistula (Fig. 2e-h ).
Case 2: Transarterial Embolization
This 64-year-old woman presented with a 2-month history of left diplopia, chemosis, proptosis, and partial CN VI palsy. The left intraocular pressure was found to be 24 mm Hg and visual acuity 20/200. Diagnostic angiography demonstrated a Barrow Type C fistula fed by the left MMA, with drainage into the SOV (Fig. 3 ). An Echelon microcatheter was navigated distally into the feeding artery and embolization with 0.6 ml of Onyx 34 was undertaken. Final angiography revealed complete obliteration of the CCF.
Discussion
Cavernous-carotid fistulas are abnormal vascular connections between the ICA and/or ECA and the cavernous sinus. Various classification systems have been proposed, but the Barrow scheme is most commonly used (Table 3) . 2 Patients harboring CCFs commonly pre- sent with ophthalmological symptoms such as proptosis, chemosis, conjunctival injection, diplopia, secondary glaucoma, and loss of vision. These phenomena occur as a result of venous hypertension due to arterialization of the cavernous sinus and draining orbital veins. Headache may occur due to engorgement or partial thrombosis of the cavernous sinus with stretching of the dura mater, or due to cortical venous drainage with cerebral venous hypertension. Occasionally, subarachnoid or intracerebral hemorrhage from rupture of arterialized cortical veins may occur as the presenting symptom.
The treatment of CCFs is challenging. Advances in catheters and embolic materials have made endovascular embolization the preferred method of treatment. Traditionally, direct fistulas were treated with detachable balloons deployed via a transarterial route. However, since their removal from the market, balloons have commonly been replaced by coils or embolic agents to achieve cavernous sinus obliteration; the coils and/or liquid embolic agents are delivered via the arterial or venous side. Covered stents are another excellent alternative, provided there is minimal vessel tortuosity and ample room to navigate these stiff devices. Transarterial embolization of indirect CCFs is often unsuccessful because of the difficulty in catheterization of numerous small-caliber me ningeal branches. The transvenous approach for embolization, pioneered by Debrun and colleagues in the 1980s, has become the treatment of choice. 3 The IPS is the simplest and shortest venous route to the cavernous sinus, but the basilar plexus, the pterygoid plexus, or the facial and angular veins are other endovenous options.
Onyx-induced cavernous sinus obliteration has several distinct advantages compared with coils or NBCA. Unlike coils, which can compartmentalize the cavernous sinus and result in incomplete obliteration, Onyx gradually permeates the sinus interstices. In contrast to NBCA, which rapidly polymerizes, Onyx gradually precipitates in a radial fashion from outside inwards, forming a cast, and therefore can be injected more slowly and accurately while minimizing the need for repeated catheterizations. These inherent properties allow deep penetration within the vasculature and are particularly useful in filling the fine fistulous communications commonly seen in indirect CCFs. Furthermore, the injection may be interrupted several times during the procedure to allow assessment of the embolization pattern and early recognition of dangerous anastomoses. In contrast to NBCA, Onyx does not adhere to vessel walls, and thus a greater degree of reflux can be tolerated during embolization without fear of catheter retention.
The role of Onyx in the treatment of CCF has not been well-documented and has largely been limited to case reports and small case series. Most of these reports have focused on the physical properties of Onyx and the embolization techniques. Complications associated with Onyx embolization of CCFs, however, have not been significantly emphasized. The use of Onyx for the treatment of a CCF was first reported by Arat et al. in 2004.
1 The authors were successful in treating a Type D fistula via a transvenous route without complication. In 2006, Suzuki et al. 6 reported the use of Onyx 34 in combination with coils in the treatment of 3 patients with spontaneous indirect CCFs. In all cases the lesions were embolized via a transvenous route and resulted in complete angiographic obliteration following a single session. No procedural or postoperative complications were encountered. In 2008, He and colleagues 4 reported their experience in treating 6 patients with indirect CCF by using a combination of Onyx and coils. Complete cure was achieved in 4 patients following a single session and in 2 patients after an additional session. Transient headache was observed in all patients following embolization and resolved within several days. Two patients developed transient CN VI palsies following transvenous embolization, and 1 patient developed a transient facial palsy following transarterial embolization of ECA branches prior to definitive treatment via a transvenous route. Recently, Lv et al. 5 reported the results of transarterial Onyx 18-based embolization in 31 patients with dural arteriovenous fistulas. Although the authors did not specifically state the number of CCFs in their series, one can conclude that there were at least 5 cases based on the clinical presentations and fistula drainage into the SOV. Of the 5 CCFs, complete angiographic obliteration was achieved in 3. Two patients experienced complications: one hemifacial hypesthesia and one trigeminocarotid reflex, hemifacial hypesthesia, and facial palsy. Despite the efficacy and inherent advantages of Onyx in the treatment of CCFs, it is not without hazards. Cranial neuropathies following embolization may occur as a result of several mechanisms. Nerve ischemia/infarct from inadvertent embolization of CN nutrient arteries, CN compression secondary to postembolization cavernous sinus thrombosis and swelling, or possibly angiotoxic effects of DMSO may explain such events. We speculate that CN infarction was the cause of facial palsy seen in Case 7. In this case, transarterial embolization of the MMA presumably may have resulted in occlusion of the petrosal branch, which supplies the facial nerve. As would be expected, the facial palsy was immediately present following the procedure and did not recover on follow-up. In Case 4, the patient developed a transient Horner syndrome and partial CN VI palsy. In this case transvenous embolization was performed, and we presume that a compressive cranial neuropathy may have resulted from cavernous sinus thrombosis and subsequent swelling. As would be expected, the deficits were seen in a delayed fashion and had resolved completely at 4-month follow-up. In Case 2, the patient developed transient CN III and V palsies. In this case transarterial embolization through the MMA was performed. Because casting of the cavernous sinus was not achieved, we conclude that postembolization swelling with subsequent CN compression was likely not a contributing factor. That said, postembolization thrombosis of the cavernous sinus cannot be ruled out. We speculate that the angiotoxic effect of DMSO may have been responsible for the neuropathy in this case. Fortunately, the deficit was transient, and the patient recovered completely at 2-month follow-up.
Conclusions
Onyx is a liquid embolic agent that is effective for the treatment of CCFs but not without hazards. Postembolization cavernous sinus thrombosis and swelling may result in transient compressive cranial neuropathies. The inherent gradual polymerization properties of Onyx allow for casting of the cavernous sinus but may potentially result in deep penetration within arterial collaterals that can cause CN ischemia/infarction. Although not proven, the angiotoxic effects of DMSO may also play a role in postembolization CN deficits.
Disclosure
Dr. Aziz-Sultan serves as a proctor for ev3 Inc.
